- Home
- LPA vs FENC Comparison
LPA vs FENC Comparison
Compare LPA & FENC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LPA
- FENC
- Stock Information
- Founded
- LPA 2013
- FENC 1996
- Country
- LPA United States
- FENC United States
- Employees
- LPA N/A
- FENC N/A
- Industry
- LPA
- FENC Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- LPA
- FENC Health Care
- Exchange
- LPA Nasdaq
- FENC Nasdaq
- Market Cap
- LPA 196.1M
- FENC 225.4M
- IPO Year
- LPA N/A
- FENC 2001
- Fundamental
- Price
- LPA $6.31
- FENC $8.67
- Analyst Decision
- LPA
- FENC Strong Buy
- Analyst Count
- LPA 0
- FENC 2
- Target Price
- LPA N/A
- FENC $13.50
- AVG Volume (30 Days)
- LPA 10.2K
- FENC 56.7K
- Earning Date
- LPA 11-12-2025
- FENC 11-06-2025
- Dividend Yield
- LPA N/A
- FENC N/A
- EPS Growth
- LPA N/A
- FENC N/A
- EPS
- LPA 0.22
- FENC N/A
- Revenue
- LPA $45,924,457.00
- FENC $33,302,000.00
- Revenue This Year
- LPA N/A
- FENC $0.18
- Revenue Next Year
- LPA N/A
- FENC $52.59
- P/E Ratio
- LPA $29.31
- FENC N/A
- Revenue Growth
- LPA 6.18
- FENC N/A
- 52 Week Low
- LPA $5.71
- FENC $3.96
- 52 Week High
- LPA $15.85
- FENC $9.42
- Technical
- Relative Strength Index (RSI)
- LPA 49.52
- FENC 48.25
- Support Level
- LPA $6.10
- FENC $8.42
- Resistance Level
- LPA $6.62
- FENC $9.11
- Average True Range (ATR)
- LPA 0.25
- FENC 0.32
- MACD
- LPA 0.01
- FENC -0.04
- Stochastic Oscillator
- LPA 52.31
- FENC 29.14
About LPA Logistic Properties of the Americas
Logistic Properties of the Americas is a fully-integrated, internally managed real estate company that develops, owns, and manages a diversified portfolio of warehouse logistics assets in Central America and South America. It focuses on modern Class A logistics real estate in high-growth and high-barrier-to-entry markets that are undersupplied and have low penetration rates. The company has three operating segments, based on geographic regions, consisting of Colombia, Peru, and Costa Rica. The company generates the majority of its revenue from the Costa Rica geographical segment.
About FENC Fennec Pharmaceuticals Inc.
Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.